5 recruiting, 2 not yet recruiting, 1 active not recruiting. 3 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Non Small Cell Lung Cancer NSCLC: new trials by email Literature Review of Non Small Cell Lung Cancer NSCLC trials Research Report on Non Small Cell Lung Cancer NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression limertinib, etoposide and carboplatin - Small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 30 | 2026-05-01 | 2026-03-16 |
| A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) Non Small Cell Lung Cancer NSCLC | Recruiting | Ono Pharmaceutical Co., Ltd. | 100 | 2026-03-20 | 2026-05-20 | |
| A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients EGFR-TKI - Non Small Cell Lung Cancer NSCLC | Not yet recruiting | Guangzhou University of Traditional Chinese Medicine | 3000 | 2026-01-01 | 2026-01-13 | |
| Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic | Recruiting | GFPC Investigation | 100 | 2025-11-19 | 2026-05-01 | |
| Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen Durvalumab (MEDI4736), Ceralasertib, radiotherapy - Non Small Cell Lung Cancer NSCLC | Phase 2 | Recruiting | Mario Negri Institute for Pharmacological Research | 21 | 2025-08-07 | 2025-12-18 |
| Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure Vebreltinib combined with Furmonertinib - Non Small Cell Lung Cancer NSCLC | Phase 1 / Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 42 | 2025-04-08 | 2025-07-25 |
| The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients bronchial lavage for NGS analysis - Non Small Cell Lung Cancer NSCLC | Not applicable | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 10 | 2025-01-17 | 2025-09-23 |
| Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). Durvalumab, Tremelimumab, Abraxane + carboplatin - Non Small Cell Lung Cancer NSCLC | Phase 3 | Active not recruiting | AstraZeneca | 1186 | 2017-06-01 | 2026-03-13 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Lung Neoplasms (1)
Carboplatin (2) · durvalumab (2) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Etoposide (1) · Gemcitabine (1) · Pemetrexed (1) · Radiotherapy (1) · aflutinib (1) · ceralasertib (1) · tremelimumab (1)
AstraZeneca (1) · GFPC Investigation (1) · Guangzhou University of Traditional Chinese Medicine (1) · Hunan Province Tumor Hospital (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Mario Negri Institute for Pharmacological Research (1) · Ono Pharmaceutical Co., Ltd. (1) · Peking University Cancer Hospital & Institute (1)
China (4) · Italy (2) · Taiwan (2) · Brazil (1) · Bulgaria (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Japan (1) · Mexico (1) · Peru (1) · Poland (1) · Russia (1) · South Africa (1)
Dr Thomas Pierret (1) · Gian Piero Bandelli, md (1) · Prof. Jean-Bernard Auliac (1) · Xiaojin Shi, M.D., MSc (1)
PMID 36327426, PMID 37777827, PMID 39243945, PMID 40781023
2017 (1)